6533b82efe1ef96bd1293e1a

RESEARCH PRODUCT

First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid

Christine Von NeuhoffIrene SchmidKonrad BochennekUrsula CreutzigNorbert GrafDirk ReinhardtClaudia RossigNils Von NeuhoffUdo KontnyMichael DworzakJörg FaberJans-enno MuellerChristian FlothoArend Von Stackelberg

subject

Acute promyelocytic leukemiaMalemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentMedizinTretinoinGastroenterologyArsenicals03 medical and health scienceschemistry.chemical_compound0302 clinical medicineArsenic TrioxideLeukemia Promyelocytic AcuteTretinoinInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansRetinoidArsenic trioxideChildneoplasmsParesisRetrospective StudiesChemotherapybusiness.industryStandard treatmentInfantPosterior reversible encephalopathy syndromeOxidesHematologymedicine.diseaseSurgeryTreatment OutcomeOncologychemistry030220 oncology & carcinogenesisChild PreschoolPediatrics Perinatology and Child HealthFemalemedicine.symptombusiness030215 immunologymedicine.drug

description

Recently, studies in adults with acute promyelocytic leukemia (APL) showed high cure rates in low-risk patients treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO), while toxicities were significantly reduced compared to the standard treatment with ATRA and chemotherapy. Here we report about first experience with 11 pediatric patients with low-risk APL treated with ATRA and ATO. All patients stayed in molecular remission. All suffered from hyperleukocytosis. Two patients experienced reversible severe side effects. One suffered from osteonecroses at both femurs, seizures, as well as posterior reversible encephalopathy syndrome, the other patient had an abducens paresis.

yearjournalcountryeditionlanguage
2017-01-23
10.1002/pbc.26461https://www.ncbi.nlm.nih.gov/pubmed/28111878